These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232 [TBL] [Abstract][Full Text] [Related]
24. Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma. Wong OGW; Li J; Cheung ANY Front Oncol; 2021; 11():666815. PubMed ID: 34737943 [TBL] [Abstract][Full Text] [Related]
25. Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery. Shuqing L; Zhiling Z Cancer Med; 2023 Mar; 12(6):6668-6674. PubMed ID: 36416131 [TBL] [Abstract][Full Text] [Related]
26. CRISPR/Cas9 Screening for Identification of Genes Required for the Growth of Ovarian Clear Cell Carcinoma Cells. Kawabata A; Hayashi T; Akasu-Nagayoshi Y; Yamada A; Shimizu N; Yokota N; Nakato R; Shirahige K; Okamoto A; Akiyama T Curr Issues Mol Biol; 2022 Apr; 44(4):1587-1596. PubMed ID: 35723366 [TBL] [Abstract][Full Text] [Related]
27. The Application Value of HNF-1β Transcription Factor in the Diagnosis of Ovarian Clear Cell Carcinoma. Huang W; Cheng X; Ji J; Zhang J; Li Q Int J Gynecol Pathol; 2016 Jan; 35(1):66-71. PubMed ID: 26166716 [TBL] [Abstract][Full Text] [Related]
28. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma. Ackroyd SA; Arguello D; Ramos P; Mahdi H; ElNaggar A; Winer I; Holloway R; Krivak T; Jones N; Turner VG; Herzog T; Chu C; Brown J; Mantia-Smaldone G Gynecol Oncol; 2023 Feb; 169():164-171. PubMed ID: 36333181 [TBL] [Abstract][Full Text] [Related]
29. Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. Takenaka M; Köbel M; Garsed DW; Fereday S; Pandey A; Etemadmoghadam D; Hendley J; Kawabata A; Noguchi D; Yanaihara N; Takahashi H; Kiyokawa T; Ikegami M; Takano H; Isonishi S; Ochiai K; Traficante N; Gadipally S; Semple T; Vassiliadis D; Amarasinghe K; Li J; Mir Arnau G; Okamoto A; Friedlander M; Bowtell DDL; Clin Cancer Res; 2019 Jul; 25(13):3962-3973. PubMed ID: 30967419 [TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study. Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002 [TBL] [Abstract][Full Text] [Related]
31. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma]. Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268 [No Abstract] [Full Text] [Related]
32. Endometriosis-associated ovarian cancer is not a distinct clinical entity among young patients: A 12-year cohort study. Cai Y; Yin J; Jin Y; Li Y; Wu M; Yang J; Huang H; Leng J; Pan L Eur J Surg Oncol; 2020 May; 46(5):876-882. PubMed ID: 31837932 [TBL] [Abstract][Full Text] [Related]
33. GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors. Clemente V; Hoshino A; Shetty M; Nelson A; Erickson BK; Baker R; Rubin N; Khalifa M; Weroha SJ; Lou E; Bazzaro M Cancer Res Commun; 2022 Aug; 2(8):784-794. PubMed ID: 36082022 [TBL] [Abstract][Full Text] [Related]
35. The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace. Korenaga TR; Ward KK; Saenz C; McHale MT; Plaxe S Gynecol Oncol; 2020 Apr; 157(1):62-66. PubMed ID: 32008796 [TBL] [Abstract][Full Text] [Related]
36. Global gene expression profiling of a mouse model of ovarian clear cell carcinoma caused by ARID1A and PIK3CA mutations implicates a role for inflammatory cytokine signaling. Chandler RL; Raab JR; Vernon M; Magnuson T; Schisler JC Genom Data; 2015 Sep; 5():329-32. PubMed ID: 26484281 [TBL] [Abstract][Full Text] [Related]
37. Prognostic determinants in patients with uterine and ovarian clear carcinoma. Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593 [TBL] [Abstract][Full Text] [Related]
38. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells. Kao YC; Lin MC; Lin WC; Jeng YM; Mao TL Histopathology; 2012 Nov; 61(5):760-8. PubMed ID: 22747504 [TBL] [Abstract][Full Text] [Related]
40. Exploring the cellular and molecular differences between ovarian clear cell carcinoma and high-grade serous carcinoma using single-cell RNA sequencing and GEO gene expression signatures. Guo D; Zhang S; Gao Y; Shi J; Wang X; Zhang Z; Zhang Y; Wang Y; Zhao K; Li M; Wang A; Wang P; Gou Y; Zhang M; Liu M; Zhang Y; Chen R; Sun J; Wang S; Wu X; Liang Z; Chen J; Lang J Cell Biosci; 2023 Jul; 13(1):139. PubMed ID: 37525249 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]